Co-invented more than 200 patents and published 40 scientific articles that referenced 5000 times, Guo-Liang Yu co-founded and was chairman and CEO of Epitomics Inc. for 10 years until their recent acquisition by Abcam for $170M. As the new Executive Chairman of Crown Bioscience, his passion is bringing a fresh and vibrant change to an… Read more »
EVERYONE’S BEEN TRYING IT OVER THE LAST 10 YEARS OR MORE, BUT WHAT HAS BEEN THE TRUE IMPACT OF SIGNIFICANT CHANGES IN PHARMACEUTICAL RESEARCH AND DEVELOPMENT, AND WHAT COULD BE THE FUTURE FOR DRUG DISCOVERY?
In Oncology, drug resistance can limit the clinical benefit of a targeted agent. Understanding the molecular mechanisms of resistance is a key factor in discovering potential follow on drugs, combination therapies and treatment regimens for patients to manage their disease. But how do you model the multiplicity of options before entering the clinic?
MANY OF THE FOODS WE EAT TODAY HAVE BECOME SIGNIFICANT AND CONTROVERSIAL SOCIAL AND HEALTH ISSUES. THE RISE OF THE INCIDENCE OF DIABETES AND DIABETES RELATED DISEASE IN NOT JUST THE WESTERN WORLD, BUT ALSO THE EMERGING ECONOMIES OF THE WORLD IS BECOMING A GLOBAL PHENOMENON WITH AN ASSOCIATED HIGHLY SIGNIFICANT HEALTHCARE BURDEN.